National liver Institute Drug Information Center

30/08/2025

How to get drug monograph from EKB ?

17/08/2025

Albumin transfusion :indication

01/08/2025

💧 Fluid Management in Acute 💥 Pancreatitis

source: British Journal of Surgery, Volume 110, Issue 8, August 2023, Pages 880–882

30/06/2025

23/05/2025

Thrombopoietin receptor agonists (TPO-RAs) are hematopoietic growth factors that bind to the thrombopoietin receptors on megakaryocytes and hematopoietic stem cells (HSCs),
FDA-Approved Indications

Eltrombopag and romiplostim effectively address thrombocytopenia in adult patients with immune thrombocytopenia (ITP) refractory to immunosuppression, splenectomy, and intravenous (IV) immunoglobulins.[2]
Eltrombopag is used to treat severe aplastic anemia (SAA) in adults and pediatric patients aged 2 and older.[3]
Avatrombopag and lusutrombopag provide a secure and efficient alternative to platelet transfusions for individuals with chronic liver disease (CLD) undergoing invasive procedures.[4][5]
Eltrombopag and romiplostim are approved for treating chronic immune thrombocytopenia (CIT) in children aged 1 and older, specifically in cases of ITP lasting over 6 months and exhibiting an inadequate response to corticosteroids, immunoglobulins, or splenectomy.[6][7]
Eltrombopag is beneficial in managing antiviral therapy–induced bone marrow suppression and thrombocytopenia aggravation in patients with hepatitis C virus (HCV) and advanced fibrosis.[8]
Romiplostim is approved for the treatment of hematopoietic syndrome of acute radiation syndrome. Romiplostim has shown efficacy in improving survival rates among adults and pediatric patients, including neonates with acute exposure to myelosuppressive doses of radiation.[9][10]
Off-Label Uses

TPO-RAs can increase platelet count in patients with chemotherapy-induced thrombocytopenia during cancer treatment.

18/05/2025

Nature Reviews Bioengineering: This Review explores the engineering of CRISPR–Cas tools and corresponding delivery strategies for the treatment of bacterial infections and modification of the microbiome.

Link to the article in the comments.

10/05/2025

EASL Clinical Practice Guidelines on the management of hepatitis B virus infection

➡️ Comprehensive, evidence-based recommendations for hepatitis B virus (HBV) infection management.
➡️ Diagnostics, treatment goals, treatment indications, therapeutic options, hepatocellular carcinoma surveillance, management of special populations, HBV reactivation prophylaxis, post-transplant care, HBV prevention strategies.
➡️ Emerging biomarkers and evolving definitions of functional and partial cure.

✅ Addresses open questions and future research directions.
✅ Attention is given to simplified algorithms, vaccination, and screening to support global HBV elimination targets.
✅ Aim to equip healthcare providers across disciplines with practical tools to optimise HBV care and outcomes worldwide.

Free text here: https://authors.elsevier.com/a/1l3v2cOnAYPKI

EASL - The Home of Hepatology

09/02/2025

Diuretics in heart faileur

21/01/2025